Join us for a dynamic roundtable discussion and networking event where venture capitalists (VCs) and VC-backed biotech leaders will share insights on how model-informed drug development (MIDD) and early and late-stage science-driven strategy can enhance decision-making and accelerate program success.
Panelists will discuss:
- Pain points at VCs and VC-backed biotechs and where MIDD and scientific consulting can help
- Certara’s cross-functional drug discovery and development expertise and application of MIDD solutions
- How investors are utilizing Certara’s solutions to support asset evaluation and prioritization
- The benefits of a strategic partnership with Certara, including tech-enabled solutions and customized support to meet your development needs
Panelists:
- Wojciech Dworakowski, PhD, VP, Toxicology and DMPK at Flagship Pioneering and Pioneering Medicines
- Karen Hong, PhD, Co-Founder and Co-Owner of Cold Spring Bio
- Kevin Munnelly, SVP of Technology at Third Rock Ventures
- Alex Pellerin, PhD, Director at Seismic Therapeutic
Agenda:
5:00 – 5:30pm – Registration
5:30 – 5:40pm – Introduction
5:40 – 6:30pm – Industry panel discussion
6:30 – 7:00pm – Q&A session
7:00 – 8:00pm – Networking reception